May 13, 2010 (M2 PRESSWIRE via COMTEX) -- Braintree,Ma. LevelStock.com is pleased to announce to all of its members and investors information on Nutra Pharma Corp., (OTCBB:NPHC). The Company recently released news as follows:
Nutra Pharma has announced that Grass Roots Research and Distribution, Inc. has published a research report updating coverage of Nutra Pharma.
Nutra Pharma Corp., a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), has announced today that Grass Roots Research and Distribution, Inc. has published a research report updating coverage of Nutra Pharma Corporation.
The publication from Grass Roots Research and Distribution, Inc., which was commissioned by Nutra Pharma, focuses on the company's current drug development initiatives, including the company's leading drug candidates for the treatment of Multiple Sclerosis (MS), HIV, Adrenomyeloneuropathy (AMN), and Rheumatoid Arthritis (RA) as well as the company's recent launch of Cobroxin and Nyloxin, treatments for chronic pain.
A PDF of the research report can be accessed at: http://www.grassrootsrd.com/grassrootsrd/Reports/Nutra_Pharma_Corp_05_12_2010.pdf
About Nutra Pharma Corp.
Nutra Pharma Corporation (the "Company") operates as a biotechnology company specializing in the acquisition, licensing, and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune, and infectious diseases. The Company, through its subsidiaries, carries out basic drug discovery research and clinical development, and also seeks strategic licensing partnerships to reduce the risks associated with the drug development process. Nutra Pharma's wholly-owned drug discovery subsidiary, ReceptoPharm, is developing proprietary therapeutic protein products primarily for the prevention and treatment of viral and neurological diseases, including Multiple Sclerosis (MS), Adrenomyeloneuropathy (AMN), Human Immunodeficiency Virus (HIV), and pain in humans. Additionally, ReceptoPharm provides contract research services through its ISO class 5 and GMP certified facilities. The Company's wholly-owned medical devices subsidiary, Designer Diagnostics, engages in the research and development of diagnostic test kits designed to be used for the rapid identification of infectious diseases, such as Nontuberculous Mycobacteria (NTM). Nutra Pharma continues to identify intellectual property and companies in the biotechnology arena that it investigates about possibly acquiring or establish strategic partnerships with.
About LevelStock.com
We are an investor community and investors relations website specializing in emerging growth stocks in today's Hot Sectors and providing a platform of services for SmallCap, MicroCap, NanoCap Companies.
We encourage everyone to join our social media sites:
Free Subscription For Our Newsletters: http://www.levelstock.com/
FaceBook: http://www.facebook.com/group.php?gid=283660480870
Twitter: http://twitter.com/levelstock
LevelStock.com is not a registered investment advisor or broker-dealer. The information here is believed to be reliable, but not guaranteed to be accurate by LevelStock.com Please be advised that the information contained may or may not be complete and is solely for informational purposes only. Please read our full disclaimer for complete risks and disclosures http://levelstock.bondwaresite.com/news.php?viewStory=19
CONTACT: LevelStock.com e-mail: support@levelstock.com
Email
Print
Digg
Del.icio.us
Reddit
Slashdot
Technorati
Newsvine
StumbleUpon
Google
Yahoo!
